Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Multiple Rising Oral Doses of BI 1358894 and Midazolam Interaction in Healthy Males
NCT03754959Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2018
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of bi 1358894 in major depressive disorder (MDD) (5 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Number of Subjects With On-treatment Drug-related Adverse Events up to 14 days. Started Dec 2018; status: completed.
02
Drugs
bi 1358894
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03754959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03754959.